November 2021
Starting Jan. 1, 2022, we’ll change how we cover some drugs
As we’ve let you know before, Blue Cross Blue Shield of Michigan and Blue Care Network want to make sure members receive safe, high-quality care that meets their needs. To accomplish this, we’re making some changes to how we cover some drugs on the Clinical, Custom, Custom Select and Preferred Drug lists, starting Jan. 1, 2022. We’ll send letters to affected members and their groups and providers.
The following is a list of these changes:
Drugs on the Clinical and Custom Drug Lists that won’t be covered
We’ll no longer cover the drugs in the table below. Unless noted, both the brand name and available generic equivalents won’t be covered. If members fill a prescription for one of these drugs on or after Jan. 1, 2022, they’ll be responsible for the full cost.
The drugs that won’t be covered are listed, along with the covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.
Drugs that won’t be covered |
Common use or drug class |
Preferred alternatives |
Asmanex®/HFA |
Asthma |
Arnuity® Ellipta®, Flovent® HFA/Diskus®, Pulmicort®/Flexhaler, Qvar® Redihaler® |
Bevespi® Aerosphere® |
Chronic obstructive pulmonary disease |
Anoro® Ellipta®, Stiolto® Respimat® |
Dulera® |
Chronic obstructive pulmonary disease |
Advair® HFA/Diskus, ® Breo® Ellipta®, Symbicort® |
Incruse® Ellipta®, Tudorza® Pressair® |
Chronic obstructive pulmonary disease |
Spiriva®/Respimat® |
Extavia®, Plegridy® |
Multiple sclerosis |
Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Tecfidera®, Vumerity® |
Invokana®, Invokamet®/XR, Qtern®, Steglatro®, Segluromet® |
Diabetes |
Farxiga, ® Glyxambi®, Jardiance®, Synjardy XR®, Trijardy XR®, Xigduo XR® |
Granix®, Neupogen® |
Neutropenia |
Nivestym®, Zarxio® |
Oxycontin®, oxycodone ER1 |
Pain |
Butrans®, Duragesic®, MS Contin®, Opana ER®, Ultram ER®, Xtampza ER®, Zohydro ER® |
Movantik®, Relistor® tablet |
Constipation |
Amitiza®, Linzess®, Symproic® |
Siliq® |
Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) |
Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR |
1Authorized brand alternatives (authorized generics) are drugs that are considered brand-name drugs and don’t have generic equivalents. These drugs are the same as the brand-name drugs but aren’t true generic drugs. The respective brand copayment ill apply for these drugs.
Drugs on Custom Drug List that will have a higher copayment
The following brand-name drugs will have a higher copayment, starting Jan. 1, 2022. We’ve listed each along with the preferred alternatives that have similar effectiveness, quality and safety, but lower copays. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.
Nonpreferred drugs that will have a higher copayment or won’t be covered for members with a closed prescription drug benefit** |
Common use or drug class |
Preferred alternatives |
Actemra®, Cimzia®, Taltz® |
Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) |
Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR |
Gilenya®, Mayzent®, Rebif® |
Multiple sclerosis |
Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Tecfidera®, Vumerity® |
Ajovy® |
Migraine prevention |
Aimovig®, Emgality® |
Fulphila®, Udenyca®, Ziextenzo® |
Neutropenia |
Neulasta®, Nyvepria® |
Leukine® |
Neutropenia |
Nivestym®, Zarxio® |
Nutropin AQ Nuspin® |
Growth hormone |
Genotropin®, Norditropin® FlexPro® |
Orenitram ER®, Tracleer® suspension, Tyvaso®, Uptravi®, Ventavis® |
Pulmonary hypertension |
Adcirca®, Adempas®, Letairis®, Opsumit®, Revatio®, Tracleer® tablet |
Viokace® |
Pancreatic enzyme |
Creon®, Zenpep® |
Drugs on the Custom Select Drug List that won’t be covered
We’ll no longer cover the following brand-name and generic drugs. Unless noted, both the brand name and available generic equivalents won’t be covered. If members fill a prescription for one of these drugs on or after Jan. 1, 2022, they’ll be responsible for the full cost.
The drugs that won’t be covered are listed along with the covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions for preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.
Drugs that won’t be covered |
Common use or drug class |
Preferred alternatives |
Asmanex®/HFA |
Asthma |
Arnuity® Ellipta®, Flovent® HFA/Diskus®, Pulmicort®/Flexhaler, Qvar® Redihaler® |
Dulera® |
Chronic obstructive pulmonary disease |
Advair® HFA/Diskus, ® Breo® Ellipta®, Symbicort® |
Incruse® Ellipta®, Tudorza® Pressair® |
Chronic obstructive pulmonary disease |
Spiriva®/Respimat® |
Invokana®, Invokamet®/XR, Qtern®, Steglatro®, Segluromet® |
Diabetes |
Farxiga, ® Glyxambi®, Jardiance®, Synjardy XR®, Trijardy XR®, Xigduo XR® |
Oxycontin®, oxycodone ER1 |
Pain |
Butrans®, Duragesic®, MS Contin®, Opana ER®, Ultram ER®, Xtampza ER®, Zohydro ER® |
Siliq® |
Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) |
Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR |
1Authorized brand alternatives (authorized generics) are drugs that are considered brand-name drugs and don’t have generic equivalents. These drugs are the same as the brand-name drugs but aren’t true generic drugs. The respective brand copayment ill apply for these drugs.
Drugs on the Custom Select Drug List that will have a higher copayment
The following brand-name drugs will have a higher copayment, starting Jan. 1, 2022. We’ve listed each along with the preferred alternatives that have similar effectiveness, quality and safety, but lower copays. When pharmacies fill prescriptions for preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.
Nonpreferred drugs that will have a higher copayment or won’t be covered for members with a closed prescription drug benefit** |
Common use or drug class |
Preferred alternatives |
Actemra®, Cimzia®, Taltz® |
Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) |
Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR |
Ajovy® |
Migraine prevention |
Aimovig®, Emgality® |
Fulphila®, Udenyca®, Ziextenzo® |
Neutropenia |
Neulasta®, Nyvepria® |
Leukine® |
Neutropenia |
Nivestym®, Zarxio® |
Nutropin AQ Nuspin® |
Growth hormone |
Genotropin®, Norditropin® FlexPro® |
Orenitram ER®, Tracleer® suspension, Tyvaso®, Uptravi®, Ventavis® |
Pulmonary hypertension |
Adcirca®, Adempas®, Letairis®, Opsumit®, Revatio®, Tracleer® tablet |
Drugs on the Preferred Drug List that won’t be covered
We’ll no longer cover the following drugs. Unless noted, both the brand name and available generic equivalents won’t be covered. If members fill a prescription for one of these drugs on or after Jan. 1, 2022, they’ll be responsible for the full cost.
The drugs that won’t be covered are listed along with the covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.
Drugs that won’t be covered |
Common use or drug class |
Preferred alternatives |
Alvesco®, Asmanex®/HFA, Qvar® |
Asthma |
Arnuity® Ellipta®, Flovent® HFA/Diskus®, Pulmicort®/Flexhaler, Qvar® Redihaler® |
Bevespi® Aerosphere® |
Chronic obstructive pulmonary disease |
Anoro ®Ellipta®, Stiolto® Respimat® |
Dulera® |
Chronic obstructive pulmonary disease |
Advair® HFA/Diskus®, Breo® Ellipta®, Symbicort® |
Incruse® Ellipta® |
Chronic obstructive pulmonary disease |
Spiriva®/Respimat® |
Extavia®, Plegridy® |
Multiple Sclerosis |
Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Ponvory®, Tecfidera®, Vumerity® |
Invokana®, Invokamet®/XR, Segluromet®, Steglatro®, Steglujan® |
Diabetes |
Farxiga®, Glyxambi®, Jardiance®, Synjardy XR®, Trijardy XR®, Xigduo XR® |
Oxycontin®, oxycodone ER1 |
Pain |
Butrans®, Duragesic®, MS Contin®, Opana ER®, Ultram ER®, Xtampza ER®, Zohydro ER® |
Relistor® |
Constipation |
Linzess®, Movantik®, Symproic® |
Siliq® |
Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) |
Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR |
Ztlido® |
Topical anesthetics |
Lidoderm® |
1Authorized brand alternatives (authorized generics) are drugs that are considered brand-name drugs and don’t have generic equivalents. These drugs are the same as the brand-name drugs but aren’t true generic drugs. The respective brand cost share will apply for these drugs.
Drugs on the Preferred Drug List that will have a higher copayment
The following brand-name drugs will have a higher copayment, starting Jan. 1, 2022. We’ve listed each along with the preferred alternatives that have similar effectiveness, quality and safety, but lower copays. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.
Nonpreferred drugs that will have a higher copayment or won’t be covered for members with a closed prescription drug benefit** |
Common use or drug class |
Preferred alternatives |
Actemra®, Cimzia®, Taltz® |
Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) |
Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR |
Ajovy® |
Migraine prevention |
Aimovig®, Emgality® |
Aubagio®, Gilenya®, Mayzent®, Rebif®, Zeposia® |
Multiple sclerosis |
Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Ponvory®, Tecfidera®, Vumerity® |
Baxdela® |
Antibiotics |
Avelox®, Cipro/XR®, Floxin®, Levaquin® |
Cayston® |
Cystic fibrosis |
Tobi® |
Combipatch® |
Menopause symptoms |
Activella®, Climara®, Fem-HRT®, Minivelle®, Vagifem®, Vivelle-Dot® |
Daytrana®, Dyanavel XR®, Quillichew ER®, Quillivant XR® |
Attention deficit hyperactivity disorder |
Adderall®/XR,*** Aptensio XR®, Concerta®, Focalin®/XR,*** Metadate CD®,*** Methylin®, Mydayis®, Ritalin® LA/SR, Vyvanse®
***Can be opened and sprinkled on applesauce |
Depo-estradiol® |
Estrogens |
Climara®, Estrace®, Minivelle®, Vagifem®, Vivelle-Dot® |
Diacomit® |
Anticonvulsants |
Depakote®, Onfi®, Topamax® |
Fetzima® |
Antidepressants |
A generic SSRI/SNRI (such as, Celexa®, Cymbalta®, Effexor/XR®, Pristiq®, Prozac®, Zoloft®, etc.), Wellbutrin/SR/XL® |
Fragmin® |
Anticoagulants |
Lovenox® |
Fulphila®, Ziextenzo® |
Neutropenia |
Neulasta®, Nyvepria® |
Leukine® |
Neutropenia |
Nivestym®, Zarxio® |
Gelnique® |
Urinary antispasmodics |
Detrol/LA®, Ditropan/XL®, Enablex®, Sanctura/XR®, Vesicare® |
K-PHOS Original® |
Potassium replacement |
Generic potassium replacement products (such as, K-Lor®, Klor-Con packet®, K-Sol®, Potassium Chloride®, K-Tab®) |
Latuda® |
Antipsychotics |
Abilify®, Clozaril®, Geodon®, Invega®, Risperdal®, Seroquel®/XR, Zyprexa® |
Lipofen® |
Lipid lowering |
Antara®, Fenoglide®, Lofibra®, Lopid®, Tricor®, Trilipix® |
Lupaneta® pack |
Endometriosis |
Lupron Depot® 3.75mg, 11.25mg plus Aygestin® |
Natesto® |
Testosterone replacement |
Androderm®, Androgel®, Android®, Axiron®, Delatestryl®, Depo-Testosterone®, Testim®, Testred® |
Novarel® |
Infertility |
Cetrotide®, generic ganirelix acetate, Ovidrel®, Pregnyl® |
Odactra®, Ragwitek® |
Allergen-specific immunotherapy |
Accolate®, Clarinex®, Flonase®, Nasalide®, Nasonex®, over-the-counter Claritin®, over-the-counter Nasacort®, over-the-counter Zyrtec®, Singulair®, Xyzal® |
Pancreaze®, Viokace® |
Pancreatic enzyme |
Creon®, Zenpep® |
Phoslyra® |
Phosphate binder |
Phoslo®, Renagel®, Renvela® |
Prevymis® |
Antiviral |
Valcyte® |
Purixan® |
Immunosuppressant |
generic mercaptopurine tablets |
Rectiv® |
Miscellaneous gastrointestinal agent |
Nitro-Bid® ointment |
Revlimid® |
Immunomodulators |
Thalomid® |
Savella® |
Fibromyalgia |
Generic SSRI/SNRI (such as, Celexa®, Cymbalta®, Effexor/XR®, Pristiq®, Prozac®, Zoloft®, etc.), generic TCA (Aventyl®, Elavil®, Sinequan®, Tofranil®, etc.), Flexeril®, Neurontin®, Ultram® |
Solu-cortef® |
Corticosteroids |
Hydrocortisone®, Decadron®, Deltasone® |
Talicia® |
H. pylori infection |
Prevacid® plus Amoxil® plus Biaxin/XL®; tetracycline plus Flagyl® plus over-the-counter bismuth subsalicylate; Prilosec® plus Amoxil® plus Biaxin/XL® |
Tracleer® suspension, Tyvaso®, Uptravi® |
Pulmonary hypertension |
Adcirca®, Adempas®, Letairis®, Opsumit®, Revatio®, Tracleer® tablet |
Trulance® |
Constipation |
Linzess®, Movantik®, Symproic® |
Valchlor® |
Immunosuppressant |
8-Mop®, Zolinza® |
Varubi® |
Antiemetic |
Emend®, Kytril®, Zofran/ODT® |
Verquvo |
Heart conditions |
Entresto® |
Vosevi®, Zepatier® |
Hepatitis C |
Epclusa®, Harvoni® |
Xifaxan® 200mg |
Anti-infective |
Bactrim DS, Vibramycin, Zithromax |
Xifaxan® 550mg |
Miscellaneous gastrointestinal agent |
For IBS-D:
Bentyl®, Imodium®, Levbid®, Levsin®, generic SSRI (Celexa®, Paxil®, Zoloft®, etc.), generic TCA (Elavil®, Sinequan®, Tofranil®, etc.)
For hepatic encephalopathy:
lactulose solution |
Yupelri® |
Chronic obstructive pulmonary disease |
Spiriva®/Respimat® |
**A closed prescription drug benefit doesn’t cover non-preferred brand drugs. Only generic and preferred brand drugs are covered. |